Clarity Pharmaceuticals Receives IND approval from FDA for phase 2 SAR-Bombesin imaging trial
Clarity Pharmaceuticals (CU6) receives approval from the US Food and Drug...
Clarity Pharmaceuticals Receives $3.26m R&D refund
Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of more than $3.26 million for...
